CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade C4 Therapeutics, Inc. - CCCC CFD

6.12
1.45%
  • Summary
  • Historical Data
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.02629 %
Charges from full value of position ($-5.00)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.02629%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.004068 %
Charges from full value of position ($0.77)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.004068%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 6.21
Open 5.97
1-Year Change 66.3%
Day's Range 5.97 - 6.16
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jul 18, 2024 6.21 -0.64 -9.34% 6.85 6.97 6.12
Jul 17, 2024 6.85 -0.51 -6.93% 7.36 7.48 6.55
Jul 16, 2024 7.34 0.76 11.55% 6.58 7.62 6.51
Jul 15, 2024 6.45 0.77 13.56% 5.68 6.71 5.48
Jul 12, 2024 5.60 0.46 8.95% 5.14 5.69 5.08
Jul 11, 2024 5.07 -0.02 -0.39% 5.09 5.33 5.03
Jul 10, 2024 4.96 -0.02 -0.40% 4.98 5.04 4.87
Jul 9, 2024 4.97 0.57 12.95% 4.40 5.00 4.33
Jul 8, 2024 4.39 -0.15 -3.30% 4.54 4.64 4.32
Jul 5, 2024 4.48 -0.05 -1.10% 4.53 4.56 4.38
Jul 3, 2024 4.52 0.12 2.73% 4.40 4.80 4.40
Jul 2, 2024 4.50 -0.26 -5.46% 4.76 4.77 4.38
Jul 1, 2024 4.82 0.19 4.10% 4.63 4.82 4.52
Jun 28, 2024 4.58 -0.04 -0.87% 4.62 4.63 4.38
Jun 27, 2024 4.59 -0.01 -0.22% 4.60 4.68 4.48
Jun 26, 2024 4.60 -0.01 -0.22% 4.61 4.84 4.34
Jun 25, 2024 4.67 0.06 1.30% 4.61 4.75 4.58
Jun 24, 2024 4.67 0.44 10.40% 4.23 4.68 4.23
Jun 21, 2024 4.20 0.20 5.00% 4.00 4.32 4.00
Jun 20, 2024 4.01 0.04 1.01% 3.97 4.02 3.88

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

C4 Therapeutics, Inc. Company profile

About C4 Therapeutics Inc

C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The Company is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, C4 Therapeutics Inc revenues increased 38% to $45.8M. Net loss increased 26% to $83.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $2.5M to $14M (expense), Research and development - Balancing val increase of 12% to $87.1M (expense).

Industry: Biotechnology & Medical Research (NEC)

490 Arsenal Way
Suite 120
WATERTOWN
MASSACHUSETTS 02472
US

People also watch

ETH/USD

3,431.56 Price
+0.460% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

XRP/USD

0.56 Price
-2.170% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

US100

19,730.50 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0263%
Short position overnight fee 0.0041%
Overnight fee time 21:00 (UTC)
Spread 1.8

Gold

2,401.77 Price
-1.760% 1D Chg, %
Long position overnight fee -0.0200%
Short position overnight fee 0.0118%
Overnight fee time 21:00 (UTC)
Spread 0.60

Still looking for a broker you can trust?

Join the 630,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading